PTC Therapeutics price target raised to $43 from $34 at Roth Capital Roth Capital increased its price target on PTC as the firm thinks that, based on recent favorable developments, the company's spinal muscular atrophy program is gaining steam. Roth believes that the compounds identified by PTC can be expanded to other neuro-muscular disorders. Roth reiterates a Buy rating on the stock.
PTC Therapeutics files to sell 3M shares of common stock Credit Suisse and Citigroup are acting as joint lead book-running managers for the offering. Cowen and Company, Deutsche Bank Securities and RBC Capital Markets are acting as book-running managers.